Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?

A

admin

Administrator
Jun 17, 2007
66,216
0
36
49
Canada
Regenxbio (NASDAQ: RGNX) is a clinical-stage biotech company that focuses on gene therapies based on its NAV Technology Platform. On Tuesday, the company moved a step closer with its "5x25 plan" of turning five of the therapies in its pipeline into marketed products by 2025. The Food and Drug Administration (FDA) granted fast track designation for Regenxbio's RGX-202, a potential onetime gene therapy to treat Duchenne muscular dystrophy.
 
You must log in or register to reply here.

Similar threads

A
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in
Replies
0
Views
89
admin
A
A
Solid Biosciences Announces $90 Million Private Placement
Replies
0
Views
136
admin
A
T
Celladon Corporation Receives FDA Fast Track Designation For Its Investigational Agen
Replies
0
Views
270
tD33NAt
T
T
Medivir: TMC435 Has Received Fast Track Designation From The FDA And TMC435 Will Be S
Replies
0
Views
238
tD33NAt
T
T
FDA Fast Track Designation Gained For ACE-031 For Duchenne Muscular Dystrophy
Replies
0
Views
311
tD33NAt
T
Back
Top